MetaCap

Eikon Therapeutics (EIKN) vs Protalix BioTherapeutics (DE) (PLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Eikon Therapeutics is the larger company by market cap ($256.8 million vs $244.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EIKN-68.40%PLX-0.34%
+12%-30%-72%
Feb 5, 20261 yearNov 20, 2026
EIKN-67.31%PLX+0.35%
+10%-31%-71%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EIKN versus PLX key metrics
MetricEIKNPLX
Share price$4.74$2.90
Market cap$256.84M$244.52M
1-day change-0.42%-5.23%
YTD return—+61.11%
1-year return—+65.71%
5-year return—+192.93%
P/E ratio (TTM)—12.08
Forward P/E—4.68
EPS (TTM)$-7.86$0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$52.74M
Revenue growth (YoY)—-1.23%
Net income (latest FY)—$-6.60M
Gross margin—48.82%
Operating margin—-10.43%
Net margin—-12.52%
52-week high$17.40$3.19
52-week low$4.72$1.65
Distance from 52-week high-72.76%-9.09%
Analyst consensusbuystrong_buy
Avg. price target upside+406.33%+313.79%
Average volume560.40K903.48K
Shares outstanding54.19M84.32M
Employees384226
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Eikon Therapeutics

EIKN stock →

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees

About Protalix BioTherapeutics (DE)

PLX stock →

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees

EIKN vs PLX FAQ

Which is bigger, Eikon Therapeutics or Protalix BioTherapeutics (DE)?

Eikon Therapeutics (EIKN) is larger, with a market capitalization of $256.84M compared with $244.52M for Protalix BioTherapeutics (DE) (PLX).

Are Eikon Therapeutics and Protalix BioTherapeutics (DE) in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons